| | | | | | | | | | |
|
|
| Dockets Entered
On January 11, 2007
|
|
|
|
|
|
|
| Docket
#
|
| Title
|
|
|
|
|
| 1978N-0065
|
| Skin Bleaching Drug Products
|
|
|
| 1999F-5522
|
| Ionizing radiation /control of Food-borne pathogens safe use
|
|
|
| 2001E-0365
|
| Patent Term Extension Application, NEXIUM 4,738,974
|
|
|
| 2001P-0230
|
| Domestic Marketing & Importation of Transgenic Fish
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
| 2004E-0011
|
| Patent Term Extention of U.S. patent No. 5,198,533 for Cetrotide (cetrorelix acetate)
|
|
|
| 2004E-0393
|
| Patent Extension for Uroxatral (Alfuzosin hydrochloride), U.S. Patent No. 4,661,491
|
|
|
| 2004E-0396
|
| Patent Extension for TAXUS EXPRESS (Paclitaxel-Eluting Coronary Stent System)
|
|
|
| 2004E-0413
|
| Patent Term Extension for CIALIS (tadalafil), U.S. Patent No. 5,859, 006
|
|
|
| 2004P-0464
|
| Vitamin D & Calcium & Reduced Risk of Osteoporosis
|
|
|
| 2005N-0373
|
| Use of Materials Derived from Cattle in Medical Products Intended for Use in Humans and Drugs Intended for Use in Ruminants
|
|
|
| 2005P-0384
|
| Deficient Peripheral Metabolism of Thyroxine to Triiodothyronine
|
|
|
| 2006D-0463
|
| Guidance for Industry on Sinusitis: Designing Clinical Development Programs of Nonantimicrobial Drugs for Treatment; Availability
|
|
|
| 2006E-0025
|
| Patent Extension Application for INCRELEX (mecasermin rDNA orgin injection), U.S. Patent No. 5,681,814
|
|
|
| 2006E-0040
|
| Patent Extension Application for ROZEREM (ramelteon), U.S. Patent No. 6,034,239
|
|
|
| 2006E-0042
|
| Patent Extension Application for CUBICIN (daptomycin for injection), U.S. Patent No. 4,885,243
|
|
|
| 2006E-0043
|
| Patent Extension Application for TYGACIL (tigecycline), U.S. Patent No. 5,529,990
|
|
|
| 2006N-0493
|
| International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization Scheduling Recommendations for Dronabinol (INN) and its Stereoisome
|
|
|
|
| 2006N-0517
|
| Medical Devices; Immunology and Microbiology Devices; Classification of Quality Control Material for Cystic Fibrosis Nucleic Acid Assays
|
|
|
| 2006P-0271
|
| Amend practice of assessing the performance of medical devices for determining in vitro susceptibility of bacteria or fungi to included CLSI.
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
| 2006P-0415
|
| Petition Seeking Regulation of Cloned Animals
|
|
|
| 2006P-0535
|
| Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products
|
|
|
| 2007N-0005
|
| Prescription Drug User Fee Act (PDUFA): Public Meeting
|
|
|
| 1978N-0065
|
| Skin Bleaching Drug Products
|
|
|
| C 78
|
| M. Wallis, MD
|
| Vol #:
|
| 20
|
|
|
| 1999F-5522
|
| Ionizing radiation /control of Food-borne pathogens safe use
|
|
|
| C 99
|
| Gray Star, Inc.
|
| Vol #:
|
| 10
|
|
|
| 2001E-0365
|
| Patent Term Extension Application, NEXIUM 4,738,974
|
|
|
| LET 6
|
| FDA/CDRH to Budd Larner, P.C.
|
| Vol #:
|
| 1
|
|
|
| 2001P-0230
|
| Domestic Marketing & Importation of Transgenic Fish
|
|
|
| C 1404
|
| M. Czech
|
| Vol #:
|
| 262
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
| | | | | | | | |
|
|
| EC 2485
|
| Miss. Varsenik Khloyan
|
| Vol #:
|
| 10
|
|
|
| 2004E-0011
|
| Patent Term Extention of U.S. patent No. 5,198,533 for Cetrotide (cetrorelix acetate)
|
|
|
| LET 4
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2004E-0393
|
| Patent Extension for Uroxatral (Alfuzosin hydrochloride), U.S. Patent No. 4,661,491
|
|
|
| LET 5
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2004E-0396
|
| Patent Extension for TAXUS EXPRESS (Paclitaxel-Eluting Coronary Stent System)
|
|
|
| LET 5
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2004E-0413
|
| Patent Term Extension for CIALIS (tadalafil), U.S. Patent No. 5,859, 006
|
|
|
| LET 5
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2004P-0464
|
| Vitamin D & Calcium & Reduced Risk of Osteoporosis
|
|
|
| EC 3
|
| Mrs. Cheryl White
|
| Vol #:
|
| 9
|
|
|
| 2005N-0373
|
| Use of Materials Derived from Cattle in Medical Products Intended for Use in Humans and Drugs Intended for Use in Ruminants
|
|
|
| BKG 1
|
| Background Material
|
| Vol #:
|
| 2
|
|
|
| 2005P-0384
|
| Deficient Peripheral Metabolism of Thyroxine to Triiodothyronine
|
|
|
| SUP 2
|
| E. Pritchard
|
| Vol #:
|
| 1
|
|
|
| 2006D-0463
|
| Guidance for Industry on Sinusitis: Designing Clinical Development Programs of Nonantimicrobial Drugs for Treatment; Availability
|
|
|
| C 2
|
| Accentia BioPharmaceuticals
|
| Vol #:
|
| 1
|
|
|
| 2006E-0025
|
| Patent Extension Application for INCRELEX (mecasermin rDNA orgin injection), U.S. Patent No. 5,681,814
|
|
|
| LET 5
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2006E-0040
|
| Patent Extension Application for ROZEREM (ramelteon), U.S. Patent No. 6,034,239
|
|
|
| LET 5
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2006E-0042
|
| Patent Extension Application for CUBICIN (daptomycin for injection), U.S. Patent No. 4,885,243
|
|
|
| LET 5
|
| FDA/CDER to U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2006E-0043
|
| Patent Extension Application for TYGACIL (tigecycline), U.S. Patent No. 5,529,990
|
|
|
| LET 5
|
| FDA/CDER to the U.S. Patent and Trademark Office
|
| Vol #:
|
| 1
|
|
|
| 2006N-0493
|
| International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization Scheduling Recommendations for Dronabinol (INN) and its Stereoisome
|
|
|
|
|
|
| EC 1
|
| Echo Pharmaceuticals BV
|
| Vol #:
|
| 1
|
|
|
| 2006N-0517
|
| Medical Devices; Immunology and Microbiology Devices; Classification of Quality Control Material for Cystic Fibrosis Nucleic Acid Assays
|
|